Please try another search
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Name | Age | Since | Title |
---|---|---|---|
Vuk Jemeric | - | 2023 | Director |
John Mccune Rice | 75 | - | Member of Scientific Advisory Board |
James R. Sapirstein | 63 | 2022 | Chairman & Lead Independent Director |
Sunetra Gupta | - | - | Member of Scientific Advisory Board |
Simon Tarsh | 63 | 2022 | Independent Director |
Timothy R. Ramdeen | 32 | 2023 | Independent Non-Executive Director |
Thomas Meier | 62 | 2024 | Director |
Ajit Singh | 60 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review